API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://www.globenewswire.com//news-release/2023/09/28/2751138/0/en/Onconova-Therapeutics-to-Present-a-Late-Breaking-Abstract-on-Rigosertib-at-the-2023-EADV-Congress.html
https://www.globenewswire.com/news-release/2023/05/25/2676053/0/en/Onconova-Therapeutics-Announces-Dosing-of-First-Participant-in-Investigator-Sponsored-Phase-2-Trial-of-Rigosertib-Plus-Pembrolizumab-in-Metastatic-Melanoma-Patients-Refractory-to-I.html
https://www.globenewswire.com/news-release/2023/03/07/2622028/0/en/Onconova-Therapeutics-Presents-Preclinical-Data-Characterizing-Rigosertib-s-Mechanisms-of-Action-at-the-AACR-Targeting-RAS-Conference.html
https://www.globenewswire.com/news-release/2022/09/12/2514021/0/en/Onconova-Therapeutics-Announces-Updated-Data-from-Investigator-sponsored-Phase-1-2a-Trial-Evaluating-Rigosertib-in-Combination-with-Nivolumab-in-Advanced-KRAS-mutated-Non-Small-Cel.html
https://www.globenewswire.com/news-release/2021/09/22/2301282/0/en/Onconova-Therapeutics-Announces-Encouraging-Clinical-Data-Supporting-the-Anti-Cancer-Activity-of-Rigosertib-Nivolumab-Combination-in-Advanced-KRAS-Non-Small-Cell-Lung-Cancer.html
https://investor.onconova.com/news-releases/news-release-details/onconova-therapeutics-submits-application-rigosertib-participate
https://investor.onconova.com/news-releases/news-release-details/onconova-therapeutics-announces-publication-preclinical-data
https://www.globenewswire.com/news-release/2020/07/07/2058521/0/en/Onconova-Therapeutics-Announces-Publication-of-Phase-1-Results-in-Leukemia-Research-Exploring-Oral-Rigosertib-in-Combination-with-Azacitidine-in-Higher-Risk-MDS.html
https://www.contractpharma.com/contents/view_breaking-news/2019-12-18/onconova-sta-ink-exclusive-license-agreement/
https://endpts.com/stefan-fraenkel-takes-over-as-chief-of-inceptua-group-christi-shaw-has-a-plan-to-make-yescarta-safer/
https://www.globenewswire.com/news-release/2019/09/16/1915856/0/en/Onconova-Therapeutics-Announces-Presentation-on-Rigosertib-at-the-RAS-Targeted-Drug-Discovery-Summit.html
https://globenewswire.com/news-release/2019/01/02/1679468/0/en/Onconova-Submits-Special-Protocol-Assessment-SPA-to-FDA-for-Phase-3-Trial-of-Oral-Rigosertib-in-Combination-with-Azacitidine-Vidaza-for-First-Line-Myelodysplastic-Syndromes-MDS.html
https://globenewswire.com/news-release/2018/08/21/1554502/0/en/Onconova-Therapeutics-Announces-Plan-for-Expanding-Rigosertib-Clinical-Trials-for-Patients-with-Myelodysplastic-Syndromes-MDS-to-South-America-with-Pint-Pharma.html